Premium
Endocrinology and Dialysis
Jean L. HolleySeries Editor: Lipid Abnormalities Associated with End‐Stage Renal Disease
Author(s) -
Liu Jia,
Rosner Mitchell H.
Publication year - 2006
Publication title -
seminars in dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 78
eISSN - 1525-139X
pISSN - 0894-0959
DOI - 10.1111/j.1525-139x.2006.00117.x
Subject(s) - medicine , end stage renal disease , dialysis , disease , intensive care medicine , endocrinology
Patients undergoing chronic renal replacement therapy have a high incidence of dyslipidemia. In generalthere are increased concentrations of triglyceride‐rich apolipoprotein B‐containing particles. These elevations lead to increased levels of non‐high‐density lipoprotein (HDL) levels. This pattern is further modified by the method of dialysis (peritoneal versus hemodialysis) and comorbidities such as diabetes. End‐stage renal disease patients also demonstrate increased levels of lipoprotein(a) (Lp(a)) and oxidized low‐density lipoprotein (LDL)both of which are highly atherogenic. This review focuses on the pathogenesis of these lipid abnormalities and their role in the atherosclerotic process.